{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:04:52Z","timestamp":1783008292455,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007043","name":"Lymphoma Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007043","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12094-019-02231-7","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T21:02:57Z","timestamp":1573074177000},"page":"1059-1066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-5887","authenticated-orcid":false,"given":"K. V.","family":"Argyropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pulitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Korkolopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Angelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baxevanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siakantaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2231_CR1","unstructured":"Swerdlow SH CE, Harris NL et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. International Agency for Research on Cancer (IARC), Lyon"},{"issue":"20","key":"2231_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. \nhttps:\/\/doi.org\/10.1182\/blood-2016-01-643569\n\n.","journal-title":"Blood"},{"issue":"9","key":"2231_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011\u20139. \nhttps:\/\/doi.org\/10.1038\/ng.3356\n\n.","journal-title":"Nat Genet"},{"issue":"12","key":"2231_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/ng.3442","volume":"47","author":"AC da Silva Almeida","year":"2015","unstructured":"da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, Vermeer MH, Rabadan R, Ferrando A, Palomero T. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet. 2015;47(12):1465\u201370. \nhttps:\/\/doi.org\/10.1038\/ng.3442\n\n.","journal-title":"Nat Genet"},{"issue":"12","key":"2231_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","volume":"130","author":"Joonhee Park","year":"2017","unstructured":"Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, Kim J, Martinez-Escala E, Amankulor N, Pro B, Guitart J, Mendillo ML, Savas JN, Boggon TJ, Choi J (2017) Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood 130(12):1430\u20131440. \nhttps:\/\/doi.org\/10.1182\/blood-2017-02-768234","journal-title":"Blood"},{"issue":"13","key":"2231_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","volume":"123","author":"JP Vaque","year":"2014","unstructured":"Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C, Dominguez O, Grana O, Rodriguez-Peralto JL, Rodriguez-Pinilla SM, Gonzalez-Vela C, Rubio-Camarillo M, Martin-Sanchez E, Pisano DG, Papadavid E, Papadaki T, Requena L, Garcia-Marco JA, Mendez M, Provencio M, Hospital M, Suarez-Massa D, Postigo C, San Segundo D, Lopez-Hoyos M, Ortiz-Romero PL, Piris MA, Sanchez-Beato M. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034\u201343. \nhttps:\/\/doi.org\/10.1182\/blood-2013-05-504308\n\n.","journal-title":"Blood"},{"key":"2231_CR7","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","volume":"6","author":"MJ Kiel","year":"2015","unstructured":"Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun. 2015;6:8470. \nhttps:\/\/doi.org\/10.1038\/ncomms9470\n\n.","journal-title":"Nat Commun"},{"issue":"14","key":"2231_CR8","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19(14):3755\u201363. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3488\n\n.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2231_CR9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bjd.16237","volume":"178","author":"R Nakajima","year":"2018","unstructured":"Nakajima R, Miyagaki T, Hirakawa M, Oka T, Takahashi N, Suga H, Yoshizaki A, Fujita H, Asano Y, Sugaya M, Sato S. Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment. Br J Dermatol. 2018;178(6):1373\u201382. \nhttps:\/\/doi.org\/10.1111\/bjd.16237\n\n.","journal-title":"Br J Dermatol"},{"issue":"21","key":"2231_CR10","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","volume":"76","author":"N Takahashi","year":"2016","unstructured":"Takahashi N, Sugaya M, Suga H, Oka T, Kawaguchi M, Miyagaki T, Fujita H, Sato S. Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma. Cancer Res. 2016;76(21):6241\u201352. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0992\n\n.","journal-title":"Cancer Res"},{"issue":"11","key":"2231_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337. \nhttps:\/\/doi.org\/10.1038\/nm.3394\n\n.","journal-title":"Nat Med"},{"issue":"2","key":"2231_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319. \nhttps:\/\/doi.org\/10.1038\/s41590-017-0022-x\n\n.","journal-title":"Nat Immunol"},{"issue":"7","key":"2231_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","volume":"202","author":"PC Rodriguez","year":"2005","unstructured":"Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931\u20139. \nhttps:\/\/doi.org\/10.1084\/jem.20050715\n\n.","journal-title":"J Exp Med"},{"issue":"7\u20138","key":"2231_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.intimp.2009.03.021","volume":"9","author":"MK Donkor","year":"2009","unstructured":"Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009;9(7\u20138):937\u201348. \nhttps:\/\/doi.org\/10.1016\/j.intimp.2009.03.021\n\n.","journal-title":"Int Immunopharmacol"},{"issue":"25","key":"2231_CR15","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3748\/wjg.v18.i25.3303","volume":"18","author":"HL Sun","year":"2012","unstructured":"Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, Guo HF, Miao ZN. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012;18(25):3303\u20139. \nhttps:\/\/doi.org\/10.3748\/wjg.v18.i25.3303\n\n.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2231_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49\u201359. \nhttps:\/\/doi.org\/10.1007\/s00262-008-0523-4\n\n.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"2231_CR17","doi-asserted-by":"publisher","first-page":"38378","DOI":"10.18632\/oncotarget.16386","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, Lu HH, Bo J. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378\u201388. \nhttps:\/\/doi.org\/10.18632\/oncotarget.16386\n\n.","journal-title":"Oncotarget"},{"issue":"11","key":"2231_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00262-013-1475-x","volume":"62","author":"KR Jordan","year":"2013","unstructured":"Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF, McCarter MD. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013;62(11):1711\u201322. \nhttps:\/\/doi.org\/10.1007\/s00262-013-1475-x\n\n.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2231_CR19","doi-asserted-by":"publisher","first-page":"e57114","DOI":"10.1371\/journal.pone.0057114","volume":"8","author":"B Zhang","year":"2013","unstructured":"Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE. 2013;8(2):e57114. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0057114\n\n.","journal-title":"PLoS ONE"},{"issue":"6","key":"2231_CR20","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.3892\/ol.2018.8532","volume":"15","author":"L Wu","year":"2018","unstructured":"Wu L, Liu H, Guo H, Wu Q, Yu S, Qin Y, Wang G, Wu Q, Zhang R, Wang L, Zhang L, Liu C, Jiao S, Liu T. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett. 2018;15(6):9507\u201315. \nhttps:\/\/doi.org\/10.3892\/ol.2018.8532\n\n.","journal-title":"Oncol Lett"},{"issue":"3","key":"2231_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00262-014-1646-4","volume":"64","author":"Z Wang","year":"2015","unstructured":"Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, Xiao W, Qin H, Wang Y, Zhai Z. Tumor-induced CD14+HLA-DR (-\/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother. 2015;64(3):389\u201399. \nhttps:\/\/doi.org\/10.1007\/s00262-014-1646-4\n\n.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2231_CR22","first-page":"15173","volume":"8","author":"C Wu","year":"2015","unstructured":"Wu C, Wu X, Zhang X, Chai Y, Guo Q, Li L, Yue L, Bai J, Wang Z, Zhang L. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med. 2015;8(9):15173\u201381.","journal-title":"Int J Clin Exp Med"},{"issue":"15","key":"2231_CR23","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT Gorgun","year":"2013","unstructured":"Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975\u201387. \nhttps:\/\/doi.org\/10.1182\/blood-2012-08-448548\n\n.","journal-title":"Blood"},{"issue":"5","key":"2231_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00428-017-2107-1","volume":"470","author":"A Pileri","year":"2017","unstructured":"Pileri A, Agostinelli C, Sessa M, Quaglino P, Santucci M, Tomasini C, Grandi V, Fava P, Astrua C, Righi S, Patrizi A, Pileri SA, Pimpinelli N. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch. 2017;470(5):575\u201382. \nhttps:\/\/doi.org\/10.1007\/s00428-017-2107-1\n\n.","journal-title":"Virchows Arch"},{"issue":"3","key":"2231_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00262-017-2090-z","volume":"67","author":"LJ Geskin","year":"2018","unstructured":"Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sezary syndrome. Cancer Immunol Immunother. 2018;67(3):423\u201334. \nhttps:\/\/doi.org\/10.1007\/s00262-017-2090-z\n\n.","journal-title":"Cancer Immunol Immunother"},{"issue":"1\u20132","key":"2231_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","volume":"381","author":"A Kotsakis","year":"2012","unstructured":"Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012;381(1\u20132):14\u201322. \nhttps:\/\/doi.org\/10.1016\/j.jim.2012.04.004\n\n.","journal-title":"J Immunol Methods"},{"issue":"19","key":"2231_CR27","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","volume":"123","author":"T Wang","year":"2014","unstructured":"Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, Ristow K, Habermann TM, Thomas D, Ziesmer SC, Wellik LE, Lanigan TM, Witzig TE, Pittelkow MR, Bailey NG, Hristov AC, Lim MS, Ansell SM, Wilcox RA. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007\u2013155. \nhttps:\/\/doi.org\/10.1182\/blood-2013-12-544809\n\n.","journal-title":"Blood"},{"issue":"10","key":"2231_CR28","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/sj.jid.5700371","volume":"126","author":"MM Tiemessen","year":"2006","unstructured":"Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(10):2217\u201323. \nhttps:\/\/doi.org\/10.1038\/sj.jid.5700371\n\n.","journal-title":"J Invest Dermatol"},{"issue":"20","key":"2231_CR29","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1158\/1078-0432.CCR-13-0866","volume":"20","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clin Cancer Res. 2014;20(20):5157\u201370. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0866\n\n.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02231-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:22:22Z","timestamp":1604535742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02231-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.Lia Palomba serves as a consultant for Merck and Pharmcyclics. The rest of the authors have no interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Specimen collection was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board and the National and Kapodistrian University of Athens Bioethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Patient material was obtained from patients who had previously signed informed consent, in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}